Voleon Capital Management LP Buys New Holdings in Maravai LifeSciences Holdings, Inc. $MRVI

Key Points

• Voleon Capital Management LP has acquired a new position in Maravai LifeSciences, investing approximately $296,000 to purchase 134,089 shares of the company.
• Analysts have revised their price targets for Maravai LifeSciences, with the consensus rating currently at "Hold" and an average target price of $5.22.
• Maravai LifeSciences has a market capitalization of $679.26 million, with shares opening at $2.66, indicating a 12-month low of $1.66 and a high of $9.50.

Voleon Capital Management LP bought a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 134,089 shares of the company's stock, valued at approximately $296,000. Voleon Capital Management LP owned about 0.05% of Maravai LifeSciences at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. EntryPoint Capital LLC purchased a new stake in shares of Maravai LifeSciences in the 1st quarter valued at $32,000. Teacher Retirement System of Texas acquired a new position in Maravai LifeSciences during the first quarter worth $37,000. Aigen Investment Management LP acquired a new position in Maravai LifeSciences during the first quarter worth $37,000. Performa Ltd US LLC raised its position in Maravai LifeSciences by 245.0% during the first quarter. Performa Ltd US LLC now owns 17,250 shares of the company's stock worth $38,000 after acquiring an additional 12,250 shares during the period. Finally, Pekin Hardy Strauss Inc. acquired a new stake in shares of Maravai LifeSciences in the first quarter valued at about $55,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Stock Down 4.3%

Shares of NASDAQ MRVI traded down $0.12 during midday trading on Friday, hitting $2.67. The company's stock had a trading volume of 1,202,910 shares, compared to its average volume of 900,166. The business's fifty day simple moving average is $2.49 and its two-hundred day simple moving average is $2.33. The company has a debt-to-equity ratio of 0.68, a current ratio of 5.16 and a quick ratio of 4.49. Maravai LifeSciences Holdings, Inc. has a 1 year low of $1.66 and a 1 year high of $9.50. The firm has a market capitalization of $681.82 million, a price-to-earnings ratio of -1.96 and a beta of 0.29.

Analyst Ratings Changes

Separately, Royal Bank Of Canada dropped their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating for the company in a report on Tuesday, August 12th. Three equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences has an average rating of "Hold" and an average price target of $5.22.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.